Evidence map›Paper›PMID 40775197›Full record

ReviewCNS drugs2025

Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders.

Kamil Detyniecki, Adam Strzelczyk, Robert Roebling, Cedric Laloyaux, Hugues Chanteux, James C Cloyd

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Kamil Detyniecki *University of Miami Miller School of Medicine, Comprehensive Epilepsy Center, Department of Neurology, Miami, FL, 33136, USA. Kamil.detyniecki@med.miami.edu.ORCID http://orcid.org/0000-0002-8334-1403
Adam Strzelczyk *Goethe-University Frankfurt, Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, University Hospital Frankfurt, Frankfurt, Germany.
Robert RoeblingUCB, Monheim am Rhein, Germany.
Cedric LaloyauxUCB, 1420, Braine-l'Alleud, Belgium.
Hugues ChanteuxUCB, 1420, Braine-l'Alleud, Belgium.
James C CloydCenter for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in pulmonary (PM) drug delivery through inhalation devices have enabled effective treatments for acute exacerbations of central nervous system (CNS) episodes, addressing previously unmet medical needs. While PM formulations of loxapine and levodopa are approved for agitation and off periods in Parkinson's disease (PD), respectively, there remains an unmet need for rapid-acting therapies for other acute exacerbations of neurologic disorders. In this review, the potential of PM delivery to address this gap in the management of acute CNS disorders is critically assessed, focusing on Staccato

Indexed as

Central Nervous System DiseasesDrug Delivery SystemsAdministration, InhalationAnimalsHumansLungNebulizers and Vaporizers

Identifiers

PMID40775197
PMCPMC12515229

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.